JPWO2022026631A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022026631A5 JPWO2022026631A5 JP2023505864A JP2023505864A JPWO2022026631A5 JP WO2022026631 A5 JPWO2022026631 A5 JP WO2022026631A5 JP 2023505864 A JP2023505864 A JP 2023505864A JP 2023505864 A JP2023505864 A JP 2023505864A JP WO2022026631 A5 JPWO2022026631 A5 JP WO2022026631A5
- Authority
- JP
- Japan
- Prior art keywords
- lys
- pro
- isoglu
- diacid
- pharma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical class CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 claims description 239
- 150000003839 salts Chemical class 0.000 claims description 233
- 239000012453 solvate Substances 0.000 claims description 233
- 108090000765 processed proteins & peptides Chemical group 0.000 claims description 95
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 36
- DTERQYGMUDWYAZ-UHFFFAOYSA-N N-acetyl-N-thioacetyl-Lysine Natural products CC(=O)NCCCCC(N)C(O)=O DTERQYGMUDWYAZ-UHFFFAOYSA-N 0.000 claims description 35
- 150000001413 amino acids Chemical group 0.000 claims description 32
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 32
- -1 pentafluoro Chemical group 0.000 claims description 26
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 20
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 17
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical group CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 claims description 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 17
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 10
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 10
- 125000005336 allyloxy group Chemical group 0.000 claims description 10
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 10
- 125000001589 carboacyl group Chemical group 0.000 claims description 10
- 125000003963 dichloro group Chemical group Cl* 0.000 claims description 10
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 10
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 10
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 10
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims description 9
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 9
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 6
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims description 6
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 claims description 5
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 claims description 5
- CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 claims description 5
- PECGVEGMRUZOML-AWEZNQCLSA-N (2s)-2-amino-3,3-diphenylpropanoic acid Chemical compound C=1C=CC=CC=1C([C@H](N)C(O)=O)C1=CC=CC=C1 PECGVEGMRUZOML-AWEZNQCLSA-N 0.000 claims description 5
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 5
- XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 claims description 5
- LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical group CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 claims description 5
- PECYZEOJVXMISF-REOHCLBHSA-N 3-amino-L-alanine Chemical compound [NH3+]C[C@H](N)C([O-])=O PECYZEOJVXMISF-REOHCLBHSA-N 0.000 claims description 5
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 5
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 5
- CZCIKBSVHDNIDH-NSHDSACASA-N N(alpha)-methyl-L-tryptophan Chemical group C1=CC=C2C(C[C@H]([NH2+]C)C([O-])=O)=CNC2=C1 CZCIKBSVHDNIDH-NSHDSACASA-N 0.000 claims description 5
- CZCIKBSVHDNIDH-UHFFFAOYSA-N Nalpha-methyl-DL-tryptophan Natural products C1=CC=C2C(CC(NC)C(O)=O)=CNC2=C1 CZCIKBSVHDNIDH-UHFFFAOYSA-N 0.000 claims description 5
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 5
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- JCZLABDVDPYLRZ-AWEZNQCLSA-N biphenylalanine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1C1=CC=CC=C1 JCZLABDVDPYLRZ-AWEZNQCLSA-N 0.000 claims description 5
- 229960003104 ornithine Drugs 0.000 claims description 5
- 229960001639 penicillamine Drugs 0.000 claims description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 5
- 229960004799 tryptophan Drugs 0.000 claims description 5
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 5
- PSVXZQVXSXSQRO-UHFFFAOYSA-N undecaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO PSVXZQVXSXSQRO-UHFFFAOYSA-N 0.000 claims description 5
- 241001102832 Meseres Species 0.000 claims description 4
- 108091006976 SLC40A1 Proteins 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 235000021357 Behenic acid Nutrition 0.000 claims description 3
- 101000999322 Homo sapiens Putative insulin-like growth factor 2 antisense gene protein Proteins 0.000 claims description 3
- 208000016286 Iron metabolism disease Diseases 0.000 claims description 3
- 102100036485 Putative insulin-like growth factor 2 antisense gene protein Human genes 0.000 claims description 3
- 229940116226 behenic acid Drugs 0.000 claims description 3
- BBJIPMIXTXKYLZ-UHFFFAOYSA-N isoglutamic acid Chemical group OC(=O)CC(N)CC(O)=O BBJIPMIXTXKYLZ-UHFFFAOYSA-N 0.000 claims description 3
- GLZWNFNQMJAZGY-UHFFFAOYSA-N octaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCO GLZWNFNQMJAZGY-UHFFFAOYSA-N 0.000 claims description 3
- 208000018565 Hemochromatosis Diseases 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- 208000008601 Polycythemia Diseases 0.000 claims description 2
- 208000002903 Thalassemia Diseases 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000018511 hepcidin Human genes 0.000 claims description 2
- 229940066919 hepcidin Drugs 0.000 claims description 2
- 108060003558 hepcidin Proteins 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000010438 iron metabolism Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000031306 Rare hereditary hemochromatosis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000539 dimer Substances 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 206010065973 Iron Overload Diseases 0.000 description 1
- QBGPXOGXCVKULO-BQBZGAKWSA-N Lys-Cys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CS)C(O)=O QBGPXOGXCVKULO-BQBZGAKWSA-N 0.000 description 1
- PQNASZJZHFPQLE-LURJTMIESA-N N(6)-methyl-L-lysine Chemical compound CNCCCC[C@H](N)C(O)=O PQNASZJZHFPQLE-LURJTMIESA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025253353A JP2026048851A (ja) | 2020-07-28 | 2025-12-16 | コンジュゲートされたヘプシジン模倣物 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063057574P | 2020-07-28 | 2020-07-28 | |
| US202063057582P | 2020-07-28 | 2020-07-28 | |
| US202063057583P | 2020-07-28 | 2020-07-28 | |
| US202063057577P | 2020-07-28 | 2020-07-28 | |
| US63/057,583 | 2020-07-28 | ||
| US63/057,577 | 2020-07-28 | ||
| US63/057,574 | 2020-07-28 | ||
| US63/057,582 | 2020-07-28 | ||
| US202163169533P | 2021-04-01 | 2021-04-01 | |
| US202163169515P | 2021-04-01 | 2021-04-01 | |
| US202163169527P | 2021-04-01 | 2021-04-01 | |
| US63/169,515 | 2021-04-01 | ||
| US63/169,533 | 2021-04-01 | ||
| US63/169,527 | 2021-04-01 | ||
| PCT/US2021/043581 WO2022026631A1 (en) | 2020-07-28 | 2021-07-28 | Conjugated hepcidin mimetics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025253353A Division JP2026048851A (ja) | 2020-07-28 | 2025-12-16 | コンジュゲートされたヘプシジン模倣物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023540679A JP2023540679A (ja) | 2023-09-26 |
| JPWO2022026631A5 true JPWO2022026631A5 (https=) | 2024-08-06 |
| JP2023540679A5 JP2023540679A5 (https=) | 2024-08-06 |
Family
ID=80036079
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023505923A Pending JP2023536463A (ja) | 2020-07-28 | 2021-07-28 | コンジュゲート型ヘプシジン模倣体 |
| JP2023505864A Pending JP2023540679A (ja) | 2020-07-28 | 2021-07-28 | コンジュゲートされたヘプシジン模倣物 |
| JP2025186320A Pending JP2026012422A (ja) | 2020-07-28 | 2025-11-05 | コンジュゲート型ヘプシジン模倣体 |
| JP2025253353A Pending JP2026048851A (ja) | 2020-07-28 | 2025-12-16 | コンジュゲートされたヘプシジン模倣物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023505923A Pending JP2023536463A (ja) | 2020-07-28 | 2021-07-28 | コンジュゲート型ヘプシジン模倣体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025186320A Pending JP2026012422A (ja) | 2020-07-28 | 2025-11-05 | コンジュゲート型ヘプシジン模倣体 |
| JP2025253353A Pending JP2026048851A (ja) | 2020-07-28 | 2025-12-16 | コンジュゲートされたヘプシジン模倣物 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20240066131A1 (https=) |
| EP (2) | EP4188412A4 (https=) |
| JP (4) | JP2023536463A (https=) |
| KR (1) | KR20230053615A (https=) |
| AU (2) | AU2021315564A1 (https=) |
| CA (2) | CA3189432A1 (https=) |
| IL (1) | IL299530A (https=) |
| MX (1) | MX2023001292A (https=) |
| PH (1) | PH12023500004A1 (https=) |
| WO (3) | WO2022026631A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2968443T3 (da) | 2013-03-15 | 2021-12-06 | Protagonist Therapeutics Inc | Hepcidinanaloger og anvendelser deraf |
| PT3143037T (pt) | 2014-05-16 | 2021-09-24 | Protagonist Therapeutics Inc | Antagonistas peptídicos tioéter de integrina alfa4beta7 |
| US9624268B2 (en) | 2014-07-17 | 2017-04-18 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| EP3749345A4 (en) | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
| TW202019948A (zh) | 2018-07-12 | 2020-06-01 | 美商領導醫療有限公司 | 介白素-23受體之肽抑制劑及其治療發炎疾病之用途 |
| HRP20250769T1 (hr) | 2020-01-15 | 2025-08-29 | Janssen Biotech, Inc. | Peptidni inhibitori receptora za interleukin-23 i njihova uporaba u liječenju upalnih bolesti |
| AU2021209086A1 (en) | 2020-01-15 | 2022-08-04 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| US20240226225A1 (en) * | 2021-04-01 | 2024-07-11 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| AU2022249095A1 (en) * | 2021-04-01 | 2023-10-12 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| WO2023288019A2 (en) | 2021-07-14 | 2023-01-19 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of interleukin-23 receptor |
| MX2024003236A (es) | 2021-09-15 | 2024-06-19 | Viking Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos. |
| EP4472996A4 (en) * | 2022-02-02 | 2025-11-26 | Protagonist Therapeutics Inc | Conjugated hepcidin mimetics |
| EP4472995A4 (en) * | 2022-02-02 | 2025-11-19 | Protagonist Therapeutics Inc | Conjugated hepcidin mimetics |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5993811A (en) * | 1997-02-03 | 1999-11-30 | Biology Associates, Llc | Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis |
| US6774212B2 (en) * | 1999-12-03 | 2004-08-10 | Bristol-Myers Squibb Pharma Company | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease |
| WO2013086143A1 (en) * | 2011-12-09 | 2013-06-13 | The Regents Of The University Of California | Modified mini-hepcidin peptides and methods of using thereof |
| DK2968443T3 (da) * | 2013-03-15 | 2021-12-06 | Protagonist Therapeutics Inc | Hepcidinanaloger og anvendelser deraf |
| US9315545B2 (en) * | 2014-04-07 | 2016-04-19 | Merganser Biotech, Inc. | Hepcidin mimetic peptides and uses thereof |
| KR20170043509A (ko) * | 2014-06-27 | 2017-04-21 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | 헵시딘 및 미니-헵시딘 유사체 및 그의 용도 |
| US20190002503A1 (en) * | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| WO2018128828A1 (en) * | 2016-12-23 | 2018-07-12 | Bayer Healthcare Llc | Novel hepcidin mimetics and uses thereof |
| EP3749345A4 (en) * | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
-
2021
- 2021-07-28 IL IL299530A patent/IL299530A/en unknown
- 2021-07-28 WO PCT/US2021/043581 patent/WO2022026631A1/en not_active Ceased
- 2021-07-28 CA CA3189432A patent/CA3189432A1/en active Pending
- 2021-07-28 EP EP21848536.5A patent/EP4188412A4/en active Pending
- 2021-07-28 US US18/018,481 patent/US20240066131A1/en active Pending
- 2021-07-28 JP JP2023505923A patent/JP2023536463A/ja active Pending
- 2021-07-28 US US18/018,482 patent/US20240018189A1/en active Pending
- 2021-07-28 WO PCT/US2021/043579 patent/WO2022026629A1/en not_active Ceased
- 2021-07-28 AU AU2021315564A patent/AU2021315564A1/en active Pending
- 2021-07-28 CA CA3188410A patent/CA3188410A1/en active Pending
- 2021-07-28 AU AU2021316000A patent/AU2021316000A1/en active Pending
- 2021-07-28 EP EP21849116.5A patent/EP4188413A4/en active Pending
- 2021-07-28 JP JP2023505864A patent/JP2023540679A/ja active Pending
- 2021-07-28 MX MX2023001292A patent/MX2023001292A/es unknown
- 2021-07-28 US US18/016,825 patent/US20230295259A1/en active Pending
- 2021-07-28 PH PH1/2023/500004A patent/PH12023500004A1/en unknown
- 2021-07-28 KR KR1020237006472A patent/KR20230053615A/ko active Pending
- 2021-07-28 WO PCT/US2021/043584 patent/WO2022026633A1/en not_active Ceased
-
2025
- 2025-11-05 JP JP2025186320A patent/JP2026012422A/ja active Pending
- 2025-12-16 JP JP2025253353A patent/JP2026048851A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022026631A5 (https=) | ||
| US10442846B2 (en) | Hepcidin analogues and uses thereof | |
| ES3058577T3 (en) | Conjugated hepcidin mimetics for use in treating of polycythemia vera | |
| JP2023540679A (ja) | コンジュゲートされたヘプシジン模倣物 | |
| EP4092038A1 (en) | Opioid agonist peptides and uses thereof | |
| JP2012530145A5 (https=) | ||
| JP7849383B2 (ja) | コンジュゲートされたヘプシジン模倣物 | |
| WO2022212698A1 (en) | Conjugated hepcidin mimetics | |
| TW202304951A (zh) | 結合鐵調素模擬物 | |
| TW202317604A (zh) | 用於治療遺傳性血鐵沉積症之鐵調素模擬物 | |
| JPWO2022026629A5 (https=) | ||
| JPWO2020120984A5 (https=) | ||
| JPWO2022212696A5 (https=) | ||
| JPWO2022212700A5 (https=) | ||
| US6596692B1 (en) | Substance P analogs for the treatment of cancer | |
| JP2003501109A5 (https=) | ||
| AR125266A1 (es) | Miméticos de hepcidina conjugados | |
| IE912378A1 (en) | Derivatives of pituitary posterior lobe hormones | |
| EA053112B1 (ru) | Конъюгированные миметики гепсидина | |
| CN116457000A (zh) | 缀合的铁调素模拟物 | |
| CN117480176A (zh) | 用于治疗遗传性血色病的铁调素模拟物 | |
| NZ772052B2 (en) | Bicyclic peptide ligands specific for nectin-4 | |
| HK1220112B (en) | Hepcidin analogues and uses therof |